

Consolidated Profit & Loss Account

	1 st Quarter 2002	1 st Quarter 2001 (restated)
	\$m	\$m
Sales	4,421	3,991
Cost of sales	(1,169)	(1,074)
Distribution costs	(30)	(30)
Research and development	(697)	(672)
Selling, general and administrative expenses	(1,384)	(1,321)
Other operating income	156	161
Operating profit before exceptional items	1,297	1,055
Exceptional items charged to operating profit	-	(25)
Operating profit	1,297	1,030
Profit on sale of fixed assets	-	10
Net interest and dividend income	21	55
Profit on ordinary activities before taxation	1,318	1,095
Taxation	(356)	(309)
Profit on ordinary activities after taxation	962	786
Attributable to minorities	(4)	(3)
Net profit for the period	958	783
Earnings per Ordinary Share before exceptional items	\$0.55	\$0.45
Earnings per Ordinary Share	\$0.55	\$0.44
Diluted earnings per Ordinary Share	\$0.55	\$0.44
Weighted average number of Ordinary Shares in issue (millions)	1,745	1,766
Diluted average number of Ordinary Shares in issue (millions)	1,747	1,768

Consolidated Balance Sheet

	31 March 2002	31 March 2001 (restated)
	\$m	\$m
Fixed assets	8,205	7,650
Current assets	11,754	11,484
Total assets	19,959	19,134
Creditors due within one year	(7,220)	(6,994)
Net current assets	4,534	4,490
Total assets less current liabilities	12,739	12,140
Creditors due after more than one year	(788)	(903)
Provisions for liabilities and charges	(1,473)	(1,678)
Net assets	10,478	9,559
Capital and reserves		
Shareholders' funds and minority interests	10,478	9,559

Consolidated Cash Flow Statement

	1 st Quarter 2002	1 st Quarter 2001
	\$m	\$m
Cash flow from operating activities		
Operating profit before exceptional items	1,297	1,055
Depreciation and amortisation	227	212
Decrease in working capital and other non-cash movements	409	110
Net cash inflow from operating activities before exceptional items	1,933	1,377
Outflow related to exceptional items	(28)	(105)
Net cash inflow from operating activities	1,905	1,272
Returns on investments and servicing of finance	(6)	58
Tax paid	(54)	(86)
Capital expenditure and financial investment	(285)	(345)
Acquisitions and disposals	-	(20)
Net cash inflow before management of liquid resources and financing	1,560	879
Net purchase of shares	(133)	(126)
Exchange and other movements	(2)	(42)
Increase in net cash funds in the period	1,425	711
Net cash funds at beginning of period	2,867	3,605
Net cash funds at end of period	4,292	4,316

Notes to the Interim Financial Statements

1 BASIS OF PREPARATION AND ACCOUNTING POLICIES

The results for the quarter ended 31 March 2002 have been prepared in accordance with UK generally accepted accounting principles. The accounting policies applied are those set out in AstraZeneca PLC's 2001 Annual Report and Form 20-F except that, in the current period, AstraZeneca adopted Financial Reporting Standard No. 19 "Deferred Tax". Prior periods have been restated and the effects of this restatement were to increase profits for the quarter ended 31 March 2001 by \$1m and reduce net assets at that date by \$106m. On adoption net assets at 1 January 2002 were reduced by \$193m. The table below illustrates the effect on EPS before exceptional items of this restatement.

These interim financial statements do not constitute statutory accounts within the meaning of Section 240 of the Companies Act 1985. Statutory accounts for the year ended 31 December 2001 will be filed with the Registrar of Companies following the Company's Annual General Meeting. The auditor's report on those accounts was unqualified and did not contain any statement under Section 237 of the Companies Act 1985.

2001 TAXATION AND EARNINGS PER SHARE BEFORE EXCEPTIONAL ITEMS

	Q1 2001	Q2 2001	Q3 2001	Q4 2001	Year
Tax charge before adoption of FRS 19 (\$m)	(316)	(269)	(286)	(282)	(1,153)
Tax charge after adoption of FRS 19 (\$m)	(315)	(289)	(295)	(315)	(1,214)
Published EPS before adoption of FRS 19 (\$)	0.45	0.42	0.43	0.47	1.77
Adjusted EPS after adoption of FRS 19 (\$)	0.45	0.41	0.42	0.45	1.73

2 TERRITORIAL SALES ANALYSIS

	1 st Quarter 2002 \$m	1 st Quarter 2001 \$m	% Growth	
			Actual	Constant Currency
USA	2,448	2,139	14	14
Japan	172	178	(3)	10
France	265	238	11	13
Germany	167	168	(1)	1
Italy	172	150	15	18
Sweden	64	67	(4)	6
UK	180	172	5	7
Rest of World	953	879	8	11
Total	4,421	3,991	11	13

3 PRODUCT SALES ANALYSIS

	World				US	
	1 st Quarter 2002 \$m	1 st Quarter 2001 \$m	Actual Growth %	Constant Currency Growth %	1 st Quarter 2002 \$m	Actual Growth %
Gastrointestinal:						
Losec	1,218	1,495	(19)	(18)	744	(26)
Nexium	356	81	n/m	n/m	293	n/m
Others	13	12	8	8	4	-
Total Gastrointestinal	1,587	1,588	-	1	1,041	(2)
Cardiovascular:						
Zestril	283	294	(4)	(3)	183	1
Seloken	236	151	56	57	166	100
Plendil	108	106	2	4	45	7
Tenormin	94	98	(4)	-	22	69
Atacand	151	83	82	84	73	170
Others	89	103	(14)	(11)	6	(63)
Total Cardiovascular	961	835	15	17	495	36
Respiratory:						
Pulmicort	229	200	15	17	107	70
Rhinocort	64	56	14	14	44	29
Accolate	33	49	(33)	(31)	23	(36)
Oxis	31	32	(3)	(3)	-	-
Symbicort	54	3	n/m	n/m	-	-
Others	35	41	(15)	(10)	-	-
Total Respiratory	446	381	17	19	174	31
Oncology:						
Zoladex	190	160	19	23	48	(2)
Nolvadex	143	139	3	5	111	6
Casodex	124	115	8	12	31	(37)
Arimidex	66	43	53	55	27	69
Others	5	7	(29)	(29)	-	-
Total Oncology	528	464	14	17	217	(1)
CNS:						
Seroquel	336	189	78	79	293	80
Zomig	93	66	41	43	60	50
Others	7	2	n/m	n/m	2	-
Total CNS	436	257	70	71	355	73
Pain, Infection and Other Pharma:						
Diprivan	113	107	6	9	55	28
Merrem	67	49	37	39	15	67
Local anaesthetics	96	104	(8)	(4)	22	(15)
Other Pharma Products	71	104	(32)	(28)	18	(36)
Total Pain, Infection and Other Pharma	347	364	(5)	(2)	110	4
Salick Health Care	54	45	20	20	54	20
Astra Tech	34	30	13	23	2	-
Marlow Foods	28	27	4	4	-	-
Total	4,421	3,991	11	13	2,448	14

n/m not meaningful

Shareholder Information

ANNOUNCEMENTS AND MEETINGS

Annual General Meeting	25 April 2002
Announcement of half year results	25 July 2002
Announcement of third quarter and nine month results	24 October 2002
Annual Business Review	7 November 2002

DIVIDENDS

The record date for the second interim dividend payable on 8 April 2002 (in the UK, Sweden and the US) was 22 February 2002. Ordinary Shares traded ex-dividend on the London and Stockholm Stock Exchange from 20 February 2002. ADRs traded ex-dividend on the New York Stock Exchange from the same date.

Future dividends will normally be paid as follows:

First interim	Announced end of July and paid in October.
Second interim	Announced in January and paid in April.

TRADEMARKS

The following brand names used in this interim report are trade marks of the AstraZeneca group of companies:

Accolate Arimidex Astra Tech Atacand Atacand HCT Atacand Plus Casodex Crestor Diprovan Exanta Faslodex Iressa Losec Merrem Nexium Nolvadex Oxis Plendil Prilosec Pulmicort Pulmicort Respules Pulmicort Turbuhaler Rhinocort Rhinocort Aqua Seloken Seroquel Symbicort Tenormin Toprol-XL Zestril Zoladex Zomig Zomig Rapimelt

ADDRESSES FOR CORRESPONDENCE

Registrar and Transfer Office	Depository for ADRs	Registered Office	Swedish Securities Register Centre
The AstraZeneca Registrar Lloyds TSB Registrars The Causeway Worthing West Sussex BN99 6DA Tel: (0870) 600 3956	JPMorgan Chase Bank ADR Service Center PO Box 842006 Boston, MA 02284-2006 Tel: (781) 575 4328	15 Stanhope Gate London W1K 1LN Tel: (020) 7304 5000	VPC AB PO Box 7822 S-103 97 Stockholm Sweden Tel: (8) 402 9000

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

In order to utilise the 'Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995, AstraZeneca is providing the following cautionary statement. This Interim Report contains forward-looking statements with respect to the financial condition, results of operations and businesses of AstraZeneca. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.